Castleark Management LLC Buys 30,460 Shares of Insulet Corporation $PODD

Castleark Management LLC raised its stake in shares of Insulet Corporation (NASDAQ:PODD) by 60.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 80,957 shares of the medical instruments supplier’s stock after purchasing an additional 30,460 shares during the period. Castleark Management LLC’s holdings in Insulet were worth $23,011,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of PODD. Norges Bank bought a new stake in Insulet during the fourth quarter valued at about $300,794,000. Worldquant Millennium Advisors LLC purchased a new position in shares of Insulet in the second quarter valued at about $80,082,000. Jupiter Asset Management Ltd. purchased a new position in shares of Insulet in the fourth quarter valued at about $66,644,000. Squarepoint Ops LLC lifted its position in shares of Insulet by 11,905.8% in the third quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after acquiring an additional 225,377 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its position in shares of Insulet by 91.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 386,468 shares of the medical instruments supplier’s stock valued at $109,850,000 after acquiring an additional 185,081 shares in the last quarter.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.36% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on PODD shares. Jefferies Financial Group lowered their price objective on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Stifel Nicolaus decreased their target price on Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. Canaccord Genuity Group decreased their target price on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Wells Fargo & Company decreased their target price on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, BTIG Research decreased their target price on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a research report on Tuesday, May 26th. Twenty-one research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $240.78.

Insulet Trading Up 0.3%

PODD opened at $149.70 on Friday. The stock has a market cap of $10.37 billion, a price-to-earnings ratio of 34.81, a P/E/G ratio of 1.17 and a beta of 1.13. The stock’s 50 day moving average price is $169.92 and its 200-day moving average price is $232.67. Insulet Corporation has a one year low of $140.63 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts forecast that Insulet Corporation will post 6.46 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.